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ABSTRACT 
The aryl hydrocarbon (dioxin) receptor (AhR) has been studied for several decades 
largely because of its critical role in xenobiotic-induced toxicity and carcinogenesis. 
Albeit this is a major issue in basic and clinical research, an increasing number of 
investigators are turning their efforts to try to understand the physiology of the AhR 
under normal cellular conditions. This is an exciting area that covers cell proliferation 
and differentiation, endogenous mechanisms of activation, gene regulation, tumor 
development and cell motility and migration, among others. In this review, we will 
attempt to summarize the studies supporting the implication of the AhR in those 
endogenous cellular processes.  
Key words: aryl hydrocarbon receptor, proliferation, migration, cell migration 
Abbreviations: AhR, aryl hydrocarbon (dioxin) receptor, ARNT, aryl hydrocarbon 
nuclear translocator; TGFb, transforming growth factor b,  
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1. Introduction. 
The AhR is a ligand-activated transcription factor known to mediate most of the 
toxic and carcinogenic effects of a wide variety of environmental contaminants such as 
dioxin (TCDD; 2,3,7,8-tetrachlorodibenzo-[p]-dioxin). This receptor belongs to the 
basic-helix-loop-helix (bHLH)/PAS (Period [Per]-Aryl hydrocarbon receptor nuclear 
translocator [Arnt]-Single minded [Sim]) family of heterodimeric transcriptional 
regulators. bHLH/PAS proteins are involved in the control of diverse physiological 
processes such as circadian rhythms, organ development, neurogenesis, metabolism and 
in the stress response to hypoxia (reviewed in [1-3]).  The large degree of conservation 
of this receptor among species [4], its constitutive pattern of expression during 
development and in adult tissues [5] and the phenotypic alterations found in mice lacking 
AhR expression [6-8], have provided strong support for the involvement of the AhR in 
cell physiology independently of xenobiotic metabolism. AhR activation is followed by 
changes in its compartmentalization within the cell. Whereas a large fraction of the 
unliganded AhR resides in the cytosolic compartment bound to a molecular chaperone 
complex (Hsp90/XAP2/p23), upon ligand binding, the receptor translocates to the 
nucleus and heterodimerizes with ARNT. This heterodimer now binds to a partially 
characterized set of co-activators and/or co-repressors and the resulting complex 
interacts with consensus regulatory sequences (xenobiotic response elements, XREs) 
located upstream in the promoter of target genes (e.g. cytochromes P450 such as 
CYP1A1) [3]. Once transcriptional regulation has occurred, the AhR is exported to the 
cytosol and degraded by the proteasome [9-11] (Figure 1).  
Although the molecular events leading to AhR activation in presence of 
xenobiotics are generally well understood, AhR signaling pathways in absence of 
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exogenous ligands remain largely unknown. Nevertheless, increasing experimental 
evidence suggests physiological roles for the AhR in cell proliferation and 
differentiation, in liver and immune system homeostasis and in tumor development. 
Molecular mechanisms for AhR activation in absence of xenobiotics remain elusive in 
part because no clear endogenous ligands have been identified. Yet, novel means of 
receptor activation could link the AhR to endogenous functions. Thus, this receptor can 
be activated by natural compounds such as indirubin and indigo [12], an AhR repressor 
regulates AhR activity by binding and sequestering ARNT [13], proteasome inhibition 
transcriptionally activates the AhR in mouse embryo primary fibroblasts in the absence 
of xenobiotics [11,14] and transient over-expression of AhR and ARNT in CV-1 cells 
promotes transcriptional activation of CYP1A1 in absence of exogenous ligand [15]. 
Recently, several studies have shown that shear stress can activate the AhR in different 
models resulting in target genes induction (McMillan BJ, Bradfield CA, PNAS 2007; 
Mufti BBRC 1995). This effect could be mediated by the release of an endogenous 
ligand. Moreover, characterization of different AhRs in invertebrates has provided 
evidence for the involvement of the protein in developmental processes and for its 
inability to bind xenobiotics in these species (Puga Biochem Pharma 2005 Review; 
Crews ST Genes Dev 2006 Review); this suggest that the xenobiotic-detoxifing function 
of the AhR is a late-acquired property and might have masked other “ancient” 
physiological functions.  
In this short review we will try to outline how the AhR can promote or inhibit 
cell proliferation, provide clues about physiological processes that seem to require AhR 
activity and suggest a role for this receptor in cell migration and human cancer. Some of 
these issues have been the focus of excellent reviews discussing diversity and evolution 
of the AhR [4], cell cycle regulation and tumorigenesis [16,17], AhR cross-talk to 
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developmental signaling pathways [18] and dioxin-mediated toxicity as compared to 
AhR-mediated physiological functions [19].   
2. Endogenous role of the AhR in cell proliferation. 
Although most of the studies about AhR activation have been done in presence of 
exogenous ligands, an increasing body of evidence strongly suggest that this receptor can 
modulate cell proliferation in absence of xenobiotics, a conclusion that supports its role 
in normal cell physiology. 
2.1. Activation in the absence of xenobiotics. 
Early reports in cultured HeLa cells showed that a significant fraction of the AhR 
protein could be detected in the cell nucleus, in absence of exogenous ligand, forming an 
active transcriptional complex with ARNT [20]. Xenobiotic-independent AhR activation 
was also observed in AhR-deficient kidney CV-1 cells, in which transient transfection of 
AhR and ARNT induced nuclear translocation and reporter gene expression in absence 
of exogenous ligand [15]. Experiments using the nuclear export inhibitor leptomycin B 
have shown that the AhR shuttles between cytosol and nucleus under normal cellular 
conditions [21] and, in the immune system, activation of B lymphocytes with CD40 
activated the AhR and induced CYP1A1 in absence of exogenous ligands [22]. Thus, 
these and other reports showed AhR activation in cultured cells by mechanisms not 
requiring the presence of exogenous ligands. Nevertheless, the question remained of 
whether, in vivo, changes in AhR levels would affect cell and tissue function. 
2.2. Physiological clues about the endogenous roles of the AhR. 
 Homologous recombination in embryonic stem (ES) cells represents a major tool 
to decipher gene function in vivo. The production of mouse lines lacking AhR expression 
by gene targeting (gene knock-out) [6-8] has provided first-hand information about 
physiological processes requiring AhR activity. It was not only demonstrated that this 
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receptor is essential for dioxin-induced toxicity [23] and carcinogenesis [24], as 
presumable expected, but also the existence of an AhR-deficient phenotype. In addition 
to cardiac hypertrophy [25] and immune system and skin alterations [8,26], the AhR has 
a physiological role in ovary development that affects reproduction. AhR-null females 
showed difficulties in maintaining pregnancy and their pups had poor numbers of 
survival during lactation and weaning (independently of sex) [27]. Further studies 
revealed that this reproductive defect could be associated with alterations in the 
formation and number of primordial follicles in the mouse ovary [28]. 
 A well conserved alteration in all AhR-null mouse models, significantly 
contributing to demonstrate the endogenous role of this receptor, is the hepatic 
phenotype. The livers of AhR mice are smaller in size and show portal fibrosis and early 
lipid accumulation [6,8]. Vascular defects are also present that include increased 
numbers of arteries and arterioles [26] and portosystemic shunting in adult animals [29]. 
Gene expression arrays have been used to compare the liver mRNA profile between wild 
type and AhR-null mice. In agreement with its endogenous role in hepatic homeostasis, 
absence of AhR alone resulted in changes in the expression pattern of 392 genes [30]. 
One of these genes, which appears as a potential candidate to help explain the hepatic 
phenotype, is transforming growth factor b (TGFb). Livers of AhR-null mice have 
increased levels of TGFb in the portal areas [31] that could contribute to the 
development of fibrosis and to a lower proliferation rate due to the profibrogenic and 
antiproliferative activities of this cytokine. Further, additional studies have shown that 
the increased levels of TGFb could, in fact, be related to retinoic acid accumulation and 
reduced retinoic acid metabolism resulting from downregulation of CYP2C39, a major 
cytochrome P450 able to catalyze retinoic acid 4-hydroxylase reactions in the liver 
[32,33]. Therefore, many different studies, in several organs and target tissues, strongly 
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support that the AhR is relevant to preserve normal cell physiology and gives a clue 
about its relevance in disease states.  
2.3. The AhR as a positive regulator of cell proliferation. 
 One of the most intriguing and exciting aspects of AhR biology is its ability to 
promote or to inhibit cell proliferation depending on the cell phenotype. Reports have 
been published clearly showing that the properties of a particular cell profoundly affects 
whether it will grow or not upon AhR activation or over-expression. This has important 
implications if the AhR is to be considered a molecular marker in such human diseases 
as cancer. 
 The AhR cooperates with signaling molecules involved in survival pathways that 
promote cell proliferation. One such molecule is NF-kB with which the AhR physically 
interacts through the p65/RelA subunit in human breast cancer MCF-7 cells [34]. The 
interaction between AhR and p65/RelA resulted in transactivation of the c-myc proto-
oncogene, thus offering a mechanism whereby this receptor could contribute to increased 
proliferation and carcinogenesis in the breast. Cellular AhR protein content is also 
relevant to induce proliferation since its over-expression in human lung carcinoma A549 
cells increased E2F/DP2 activation, proliferating cellular nuclear antigen (PCNA) levels 
and proliferation rates [35]. Interestingly, mouse models over-expressing a constitutively 
active form of the AhR also demonstrated the role of this receptor as proliferation 
promoter. Mice expressing a constitutively active AhR showed increased frequency of 
hepatocarcinomas (induced by N-nitrosodiethylamine) than wild type animals [36]. 
Moreover, this mouse model developed spontaneous tumors in the glandular stomach in 
the absence of xenobiotic treatment [37]. Thus, in defined cell types, AhR over-
expression and/or activation stimulates proliferation and even carcinogenesis in vivo in 
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the absence of xenobiotics. From these reports, it can be proposed that this receptor has 
oncogenic activity. 
2.4. The AhR as a negative regulator of cell proliferation. 
 There are also different reports demonstrating that the AhR has antiproliferative 
activity. An initial study showed that upon activation by exogenous ligand, the AhR 
induced transcriptional activation of the tumor suppressor p27Kip1 in the absence of cell 
proliferation in 5L hepatoma cells, and that p27Kip1-induction by dioxin in fetal thymus 
occurred along with inhibition of cell proliferation [38]. A set of studies has later 
proposed that the antiproliferative activity of the AhR takes place, at least in part, 
through its physical interaction with the retinoblastoma (pRb) tumor suppressor protein, 
a process resulting in pRb-mediated inhibition of E2F-dependent transcription and cell 
cycle arrest. The AhR synergizes and interacts with pRb in presence of exogenous ligand 
under basal protein levels in MCF-7 human breast cancer cells and after transient 
transfection in SAOS-2 human osteosarcoma cells [39]. In addition, the cell cycle 
blockade at G1 induced by dioxin in MCF-7 and mouse hepatoma Hepa-1 cells was 
dependent on the interaction of activated AhR with the p300 co-activator, which induced 
p300 displacement from E2F-dependent promoters and proliferation arrest [40].  
Constitutive AhR over-expression has been also used to show an inhibitory role 
of this receptor in cell proliferation. Constitutively active AhR arrested cell cycle at G1 
and induced apoptosis in Jurkat T cells, in part by regulating the expression of 
proliferation- and apoptosis-related genes through XRE-dependent mechanisms [41]. In 
the immune system, transgenic mice containing a constitutively active AhR targeted to T 
cells by the CD2 promoter had lower thymocyte numbers and altered differentiation 
[42]. Interestingly, two recent reports have shown that sustained AhR activation inhibits 
the regenerative growth of the caudal fins in zebrafish [43] and liver regeneration after 
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2/3 partial hepatectomy in mice, probably by a mechanism that decreased cyclin-
dependent kinase 2 (CDK-2) activity but did not affect p27Kip1 or p21Cip1 tumor 
suppressors [44]. Collectively, these studies argue for a tumor suppressor activity of the 
AhR in the control of cell proliferation. 
This dual effect of the AhR on cell proliferation became also evident from a 
report in which receptor levels were dowregulated by transient transfection of specific 
small interfering RNAs (siRNAs) [45]. In MCF-7 human breast cancer cells, AhR 
siRNAs promoted the G1/S transition of the cell cycle and cell proliferation, suggesting a 
growth inhibitory role of the receptor. In contrast, in HepG2 human hepatoma cells, AhR 
siRNAs blocked the G1/S transition of the cell cycle and downregulated cyclin D1, 
cyclin E and CDK-2/4, thus revealing a growth promoting activity of the receptor.    
Therefore, it appears that cell phenotype is a critical parameter in determining 
whether the AhR will promote (oncogenic) or inhibit (tumor suppressor) cell growth and 
proliferation. Further studies are needed to clarify not only the specific signaling 
pathways involved but also the intermediate proteins interacting with the AhR.  
3. Novel cellular functions of the AhR 
3.1 Developmental functions in invertebrates 
The AhR has been identified in several invertebrates such as the fly Drosophila 
melanogaster and the worm Caenorhabditis elegans. Spineless (ss) is a bHLH-PAS 
Drosophila protein and is considered to be an AhR ortholog. It plays a central role in 
defining the distal regions of both antenna and leg. Loss-of-function alleles of ss cause 
several developmental defects: transformation of distal antenna into leg, deletion of 
distal leg (tarsal) structures, and reduction in size of most bristles (Duncan DM Genes 
Dev 1998). The characterization of the target genes and then, of the gene network 
involved in those process, begins to be deciphered (Emerald BS, Development 2003; 
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Suzanne M., Development 2003; Adachi-Yamada T, Mol.Cell.Biol 2005; Kozu S, Dev. 
Biol 2006; Emmons RB, Dev. Biol 2006). Like AhR, Spineless functions as a 
heterodimer with the Drosophila ortholog of Arnt, Tango. Spineless-Tango heterodimers 
are very similar to Ahr-Arnt heterodimers in DNA-binding specificity and transcriptional 
activation ability. However, the interaction of Spineless with Tango does not seem to 
require the presence of classical “mammalian AhR ligands” (Emmons RB, Development 
1999). Recent reports have also suggested that ss is also important in neuronal 
development, especially diversification of dendritic morphology of some specialized 
sensory neurons and as a major determinant of the Drosophila retinal mosaic eye 
(Wernet MF, Nature, 2006). 
The importance of Spineless in fly neuron functions is interesting in regard of several 
recent publications on the AhR ortholog in another invertebrate, the nematode 
Caenorhabditis elegans; the corresponding proteins, AHR-1 and AHA-1 (orthologs of 
ARNT) also share biochemical properties with their mammalian cognates. However, like 
Spineless, AHR-1 does not appear to be activated by dioxin or beta-naphthoflavone 
(Powell-Coffman JA Development 2004). The expression pattern of AHR-1 is 
particularly interesting since it is expressed in GABAergic motor neurons (specifically 
named RMEL and RMER) and regulates their fate specification (Huang X, Development 
2004). Moreover, another study showed that in ahr-1-deficient animals, the touch 
receptor neuron AVM, as well as other neuronal subtypes exhibit cell and axonal 
migration defects. The authors show the involvement of TGFbeta (UNC-129) in this 
process, a particularly relevant observation since TGFbeta and AhR signaling pathways 
crosstalk in numerous mammalian systems (Qin H, Dev. Biology 2004). Finally, another 
study has shown that loss-of-function mutations in ahr-1 or aha-1 suppress neuropeptide 
receptor-1 (npr-1)-related aggregation behavior  and regulates cell-type-specific 
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expression of soluble guanylate cyclase genes that have key roles in aggregation 
behavior and hyperoxia avoidance (Qin H, Dev. Biology 2006). 
All these results show that AhR has important physiological roles in invertebrates and 
regulates developmental processes. Remarkably, a common feature of these models is 
AhR implication in neuron differentiation and function. This particular aspect of the 
AhR function has not been extensively studied in mammalian models, probably because 
of the focus on its xenobiotic-detoxifing functions. Further studies are required since 
epidemiological observations have suggested that dioxin exposure was associated with 
neurodevelopmental, cognitive and behavioral defects (Mendola P, MRDDRR, 2002).  
 
3.2 Functions related to cell adhesion and migration. 
 The contribution of the AhR to adhesion processes involving cell-cell and cell-
substratum interactions is only beginning to emerge, and several laboratories are 
currently trying to determine at which level the AhR interacts with those signaling 
pathways. Since cell-cell and cell-substratum interactions have a profound impact in cell 
migration, and cell migration is directly related to the metastatic potential of tumor cells, 
these considerations make this issue worth of investigation. 
 Early work showed that when adherent normal human keratinocytes were 
induced to go into suspension in the absence of xenobiotics, the AhR became activated 
and CYP1A1 induced, suggesting that physiological control of cell adhesion in stratified 
squamous epithelia could, under certain conditions, activate this receptor [46]. Further, 
suspension of adherent mouse hepatoma Hepa-1c1 cells also induced nuclear 
translocation and transcriptional activation of the AhR in the absence of xenobiotics 
[47], again suggesting that this receptor could be activated during changes in the 
adhesion status of the cell.  
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 Additional studies also point to the hypothesis that preventing cell-cell contacts 
activate the AhR. Suspension of C3H10T1/2 fibroblasts transfected with a reporter 
construct stimulated AhR activation and induced reporter expression to levels similar to 
those obtained by exogenous ligand [48]. However, an interesting difference between 
both mechanisms is that suspension-induced was more transient than xenobiotic-induced 
activation. The use of pharmacological inhibitors suggested that this transient effect 
could be due to differences in transcriptional activation rather than in nuclear 
translocation and/or DNA binding efficiency of the receptor. Further experiments 
performed at low cell density revealed that the absence of cell-cell contacts had a 
prominent role over the lack of cell-substratum interactions to induce AhR activation, 
suggesting that cell density could regulate AhR distribution within the cell, with the 
trancriptionally inactive receptor located in the cytosol at confluence and the 
transcriptionally active receptor present in the nucleus at sparse cell densities [48]. In 
agreement with these observations, the AhR was found to be mainly nuclear in low 
density cultures of the keratinocyte cell line HaCaT, both nuclear and cytoplasmatic at 
subconfluence and predominantly cytosolic at confluence [49]. By introducing mutations 
within the region of nuclear localization of the AhR, this differential distribution was 
attributed to the different modulation of the nuclear export activity of the cell [49].  
 The correlation between AhR activity and cell migration is still diffuse at the 
present time. As mentioned above, work done analyzing the Caenorhabditis elegans 
AhR receptor (ahr-1) has shown that ahr1-null animals have defects in neuronal 
differentiation that are due, among other causes, to aberrant axonal migration [50]. The 
regulator of the epithelial-mesenchymal transition (EMT) Slug has been recently 
reported to be induced by the AhR in the keratinocyte cell line HaCaT [51]. From this 
study, it was found that transcriptional activation of Slug was coincident with nuclear 
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translocation of the AhR and that Slug and the AhR co-localized in the nucleus of cells 
located at the margin of the wound-healing model in culture. These results not only 
confirm AhR activation when cell-cell contacts are disrupted, but also open the 
possibility that the AhR could interact with specific cell adhesion molecules.  
 We have recently shown that immortalized mouse mammary fibroblasts from 
AhR-null mice had decreased migration in culture and that this phenotype was associated 
to a lower efficiency to induce lamellipodia [52]. Signaling pathways that regulate cell 
migration were also inhibited in AhR-null cells, which exhibited lower activation of 
focal adhesion kinase (FAK), protein kinase B/AKT (PKB/AKT), mitogen activated 
kinase ERK1 and Rac-1. Further, AhR-null immortalized fibroblasts, as opposed to wild 
type cells, had a much lower efficiency to induce tumors in vivo in immunodeficient 
NOD-SCID mice. From these data, we suggested that their lower migration ability 
compromised the potential of AhR-null immortalized fibroblasts to induce tumors in vivo 
and that, in this cell type, the AhR could have oncogenic activity.  
The implication of AhR in cell plasticity and mobility is supported by studies 
using xenobiotic liagands of this receptor. Indeed, we have recently shown that TCDD-
treated mammary carcinoma MCF-7 cells display cell scattering, increased cell surface, 
appearance of lamellipodia-like protusions and subsequently higher cell adherence and 
motility. Those morphological changes are associated with cytoskeleton reorganization, 
mainly vincullin and actin redistribution. These cellular effects are accompanied by the 
modification of the expression of several genes; notably, a decrease of E-Cadherin was 
observed, which is in line with the previously described cellular alterations. 
Concommitantly, TCDD was shown to activate Jun N-terminal Kinases (JNKs) which 
was found to be required for the dioxin effect on cell morphology and mobility (Transy 
2006). A summary of these data is presented in Figure 2.  
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While those cellular effects of the AhR seem not to be related to adaptation to 
xenobiotic exposure, they may still be mechanistically connected to the induction of 
xenobiotic metabolizing enzymes. Indeed, CYP1A1 is the most potently induced gene 
following AhR activation. It has been shown that CYP1A1 activity is associated with the 
release of reactive oxygen species (ROS), which may account for the oxidative stress 
that is observed following exposure to AhR ligands (Morel Y, Mol. Cell. Biol 1999; 
Barouki Bioch. Pharma 2001 Review; Baulig A 2003). ROS display a wide variety of 
cellular effects, among which JNK activation and activation of cellular mobility. It is 
thus possible that some of the cellular effects of AhR activation may be related to the 
induction of CYP genes and to the consequent increase in ROS. 
 Thus, it appears plausible to hypothesize that the AhR participates in signaling 
pathways regulating cell-cell and cell-substratum adhesion and, by extension, that this 
receptor has a role in cell migration. Alteration of this signaling due to changes in AhR 
levels or activity could contribute to abnormal cell migration, possibly affecting the 
tumorigenic potential of the target cell, notably its invasive and metastatic properties. 
 
4. Potential of the AhR in human tumor development in the absence of xenobiotics. 
 A major question in human cancer is the identification of molecular markers 
helpful not only for the early diagnosis of the disease but also to predict treatment 
efficacy and specificity in individual tumors and patients. Although this is a long-term 
goal in AhR research, some recent reports suggest that this receptor could be relevant in 
human cancer. 
 The AhR appears to have constitutive expression and activity in established cell 
lines from human adult T-cell leukemia (ATL) and in some primary ATL cell cultures 
[53], which suggest that this receptor has oncogenic activity in this tumor type. We have 
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recently shown that the human AhR promoter has CpG islands prone to be methylated, 
and that human tumor cell lines expressing AhR have unmethylated promoter whereas 
those cell lines not expressing this protein have a heavily methylated promoter [54]. In 
particular, the acute lymphoblastic leukemia (ALL) REH and the chronic myeloid 
leukemia (CML) K562 cell lines did not express AhR and had higher levels of AhR 
promoter methylation. Furthermore, the AhR was methylated in 33% of 21 human 
primary ALL tumors, which suggested that AhR silencing in this tumor type could be 
reflecting a tumor suppressor activity for this receptor. Interestingly, the frequency of 
AhR methylation in ALL was similar to that found for tumor suppressors p53, p73, p15 
and p16 [54]. Therefore, it can be observed that depending on the phenotype of the 
human tumor, and as previously discussed, the AhR could correlate with increased or 
with decreased proliferation potential and, thus, behaves as an oncogen or as a tumor 
suppressor gene.  
 Because changes in AhR levels and activity could be relevant to human cancer, 
some studies have addressed whether specific AhR ligands can be useful as 
chemotherapeutic agents to modulate the activity of this receptor in human tumors 
(reviewed in [55]). In pancreatic cancer tissue samples, AhR protein was expressed at 
high levels and localized mainly in the cytosolic compartment of the cell. Interestingly, 
the proliferation and anchorage-independent growth of these cells were inhibited by 
several receptor agonists, suggesting that these or related compounds could be relevant 
in the therapy of pancreatic cancer [56]. 
 Thus, although much more work has to be done, it appears that the AhR has a 
role in human cancer in a cell type-specific manner and that it could have diagnostic as 
well as prognostic value in the detection and treatment of this disease. 
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5. Concluding remarks 
 The AhR field is benefiting from intense investigation covering both xenobiotic-
related and unrelated issues. From either perspective, new and exciting results are arising 
that propose this cellular receptor as a relevant target in human disease. The fact that this 
receptor remains active under physiological conditions is an important argument to 
screen for cellular processes where its activity may be required. Moreover, it does not 
seem to require any ligands in invertebrates and regulates important developmental 
process at least in two classical models. Its rather interesting behavior with regard to the 
control of cell proliferation makes this protein an attractive model and a potential target 
in human cancer. An additional aspect of AhR Biology, that it is also quite appealing, is 
its contribution to the regulation of cell adhesion and migration, two processes highly 
important in development and cancer. It is clear from the point of view of the 
endogenous role of the AhR that much more work is needed, probably in every available 
model. However, the studies performed so far are providing evidences about which 
cellular functions may be relevant to locate this receptor within physiological pathways 
controlling cell functioning in health and disease. 
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Figure Legends. 
Figure 1. Transcriptional regulation of target genes by the AhR. Ligand binding to the 
AhR in the cytosol induces the release of a molecular chaperone complex containing at 
least Hsp90, XAP2 and p23. This makes nuclear localization signals accessible for 
importins binding and nuclear translocation. Once in the nucleus, ARNT is bound to the 
receptor and a transcriptionally active heterodimer is formed that can bind to consensus 
regulatory sequences (XREs) located upstream in the promoter of target genes. After 
transcriptional regulation has occurred, the AhR dissociates from ARNT and from the 
DNA and translocates again to the cytosol through exportins binding. In the cytosol, the 
AhR is degraded by the proteasome. 
Figure 2. The AhR interacts with signalling pathways controlling cell adhesion and 
migration. As a model, signalling regulating focal adhesion dynamics and lamellipodia 
formation is represented. From tyrosine kinase receptors (RTKs) signals are transduced 
to plasma membrane associated protein complexes containing, among others, focal 
adhesion kinase (FAK), paxillin, vinculin, p130CAS. Other molecules such as 
phosphoinositide 3-kinase (PI3K) and small GTPases of the Rac and Rho family also 
associates to these protein structures. Whereas FAK is mainly involved in focal adhesion 
dynamics with the substratum, Rac/Rho are involved in actin cytoskeleton reorganization 
and lamellipodia/philopodia formation. Molecules altering these pathways are expected 
to change the adhesion/migration pattern of the cell. The AhR could act at different 
levels in these pathways and some possibilities (not excluding many others) are indicated 
by the red arrows and the question marks. 
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